SEC 13F Intelligence

Managers / Q4 2025 · view latest →

Aldebaran Capital, LLC

CIK 0001448430 · 10293 N. MERIDIAN STREET, SUITE 300, CARMEL, IN, 46290 · 317-818-7827

Reported Value
$112M
Q4 2025
Positions
35
Filings on Record
14
2019–present window
Filed
Feb 12, 2026
original filing

Summary

Aldebaran Capital, LLC reported $112M in U.S.-listed holdings across 35 positions for Q4 2025.

Its largest position, BRK/B, represents 18.1% of the portfolio.

Compared with Q3 2025, the fund opened 3 new positions and exited 1.

Portfolio Metrics

Turnover
+6.7%
vs prior filed quarter
Top-10 Concentration
+69.8%
share of reported value
Largest Position
+18.1%
Berkshire Hathaway
New / Exited
3 / 1
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’22: $97MQ4 ’22Q1 ’23: $98MQ2 ’23: $97MQ2 ’23Q3 ’23: $98MQ4 ’23: $98MQ4 ’23Q1 ’24: $105MQ2 ’24: $107MQ2 ’24Q3 ’24: $110MQ4 ’24: $105MQ4 ’24Q1 ’25: $106MQ2 ’25: $101MQ2 ’25Q3 ’25: $109MQ4 ’25: $112MQ4 ’25Q1 ’26: $131Mfilingsflow.com

Portfolio Composition

By security type
Common Stock: 83.8%Other: 8.6%ETP: 7.6%
  • Common Stock · 83.8% · $93M
  • Other · 8.6% · $10M
  • ETP · 7.6% · $8M

Quarter-over-Quarter Changes full breakdown →

vs Q3 2025 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
MOHMOLINA HEALTHCARE INCNEW+12.7K12.7K+$2M$2M
2KZ0KEZAR LIFE SCIENCES INCNEW+80.6K80.6K+$507,163$507,163
AVIRATEA PHARMACEUTICALS INCNEW+90.5K90.5K+$323,189$323,189
TECK/BTECK RESOURCES LTDSOLD OUT−12.2K0−$533,702$0
RELLRICHARDSON ELECTRS LTDTRIMMED−24.7K119.0K−$112,429$1M
LLYLILLY ELI & COADDED+1.2K9.0K+$4M$10M
OKURONKURE THERAPEUTICS INCTRIMMED−2.7K41.3K−$1,268$119,724
FCXFREEPORT-MCMORAN INCTRIMMED−2.9K48.8K+$451,362$2M

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q4 2025

34 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1BRK/BBERKSHIRE HATHAWAY INC DELCL B NEW · CL A19.47%$22M40.2K
2LLYLILLY ELI & COhistory →COM8.70%$10M9.0K
3MSFTMICROSOFT CORPhistory →COM7.87%$9M18.1K
4BUNGE LIMITEDCOM7.51%$8M94.0K
5OXYOCCIDENTAL PETE CORPhistory →COM5.89%$7M159.6K
6BACBANK AMERICA CORPhistory →COM5.19%$6M105.3K
7ISHARES TR RUS MDCP VALETF5.08%$6M40.2K
8SUSUNCOR ENERGY INC NEWhistory →COM4.59%$5M115.3K
9CHVCHEVRON CORP NEWhistory →COM3.62%$4M26.5K
10JPMJPMORGAN CHASE & COhistory →COM3.26%$4M11.3K
11CO2ACATO CORP NEWhistory →CL A2.89%$3M1.04M
12ACRSACLARIS THERAPEUTICS INChistory →COM2.58%$3M954.3K
13ABRDN ETFSBBRG ALL COMD K12.52%$3M144.1K
14FCXFREEPORT-MCMORAN INChistory →CL B2.22%$2M48.8K
15BACVERIZON COMMUNICATIONS INChistory →COM2.19%$2M59.9K
16AMLXAMYLYX PHARMACEUTICALS INChistory →COM2.15%$2M198.5K
17CENXCENTURY ALUM COhistory →COM2.03%$2M57.7K
18MOHMOLINA HEALTHCARE INChistory →COM1.97%$2M12.7K
19SIRISIRIUS XM HOLDINGS INChistory →COMMON STOCK1.91%$2M106.3K
20ENBENBRIDGE INChistory →COM1.72%$2M40.1K
21PATKPATRICK INDS INChistory →COM1.35%$2M13.9K
22RELLRICHARDSON ELECTRS LTDhistory →COM1.16%$1M119.0K
23TECXTECTONIC THERAPEUTIC INCCOM0.70%$779,18437.4K
24PMVPPMV PHARMACEUTICALS INCCOM0.54%$597,485478.0K
252KZ0KEZAR LIFE SCIENCES INCCOM NEW0.45%$507,16380.6K
26AN2 THEREAPEUTICS INCCOM0.39%$429,518376.8K
27DUKE ENERGY CORP NEWCOM NEW0.38%$421,9563.6K
28GENERAL ELECTRIC COCOM0.35%$385,3461.3K
29FFORD MTR CO DELCOM0.32%$360,80027.5K
30MBINMERCHANTS BANCORP INDCOM0.31%$344,85810.1K
31AVIRATEA PHARMACEUTICALS INCCOM0.29%$323,18990.5K
32GEVGE VERNOVA INCCOM0.19%$216,985332
33IMAIMAGENEBIO INCCOM0.12%$131,58319.1K
34OKURONKURE THERAPEUTICS INCCOM CL A0.11%$119,72441.3K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q1 2026$131M43May 7, 202613F-HRchanges · EDGAR ↗
Q4 2025$112M35Feb 12, 202613F-HRchanges · EDGAR ↗
Q3 2025$109M33Nov 10, 202513F-HRchanges · EDGAR ↗
Q2 2025$101M34Aug 12, 202513F-HRchanges · EDGAR ↗
Q1 2025$106M41May 13, 202513F-HRchanges · EDGAR ↗
Q4 2024$105M37Feb 12, 202513F-HRchanges · EDGAR ↗
Q3 2024$110M37Nov 13, 202413F-HRchanges · EDGAR ↗
Q2 2024$107M36Aug 13, 202413F-HRchanges · EDGAR ↗
Q1 2024$105M33May 14, 202413F-HRchanges · EDGAR ↗
Q4 2023$98M31Feb 13, 202413F-HRchanges · EDGAR ↗
Q3 2023$98M33Nov 13, 202313F-HRchanges · EDGAR ↗
Q2 2023$97M33Aug 9, 202313F-HRchanges · EDGAR ↗
Q1 2023$98M34May 11, 202313F-HRchanges · EDGAR ↗
Q4 2022$97M34Feb 13, 202313F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.